Homepage - Ophthalmology Advisor
Psychiatry Advisor spoke with Michelle Lewis to discuss how color psychology can play an important role in the design of health care spaces and physician branding. Factors preventing more widespread use of biosimilars in oncology include the cost and complexity of biosimilar development, oncologists’ lack of knowledge about biosimilars, and ...
Photobiomodulation: An Emerging Dry AMD Treatment
2024年3月20日 · Photobiomodulation (PBM) is an emerging therapy that has shown promising potential as a possible treatment for patients with nonexudative intermediate AMD. In truth, this low-level laser therapy (LLLT) technology has existed for more than 50 years, and researchers have been reviewing its potential ocular applications for at least 20 of those years.
Restoring the Retina: Coming Advancements to Repair Structure …
2021年2月16日 · Retinal implants capture light and stimulate secondary neurons that have remained in the retina, such as ganglion cells and bipolar cells, which then send signals to the brain through the optic nerve. “Patients who get a retinal implant will see at least flashes of light,” says Gislin Dagnelie, PhD, associate professor of ophthalmology at ...
For Central Serous Chorioretinopathy, Wait-and-See No More
2022年3月18日 · A “wait and see” approach when caring for patients with CSCR may well apply to a smaller set of those with the disorder than previously thought, according to recent research and observations of clinical experts. Undoubtedly, CSCR often spontaneously resolves in 3 months or less. However, pathology may be originating at the retinal periphery ...
FDA Alerts: Ophthalmology Drug and Device Approvals
2024年2月20日 · Drug Regulatory Updates. Susvimo: Diabetic Eye Conditions. The FDA has accepted the application for Susvimo ® (ranibizumab injection, Genentech) to treat diabetic macular edema (DME) and diabetic retinopathy (DR) based on 1-year Pagoda and Pavilion study data. 3 Susvimo is a refillable implant that delivers medication continuously. 3. Based on 2 years of Phase 3 data presented at American ...
Ocular Myasthenia Gravis Treatment Options Explained
July 20, 2023. Myasthenia gravis (MG) can occur in 2 forms: a generalized myasthenia gravis (GMG) or purely ocular myasthenia gravis (OMG). Ocular myasthenia gravis is characterized by progressive fatigability of skeletal muscle limited to the orbicularis oculi, levator palpebrae superioris, and the extraocular muscles. 1 Up to half of patients ...
High-Dose Aflibercept Improves Vision in DME For All Subgroups ...
2024年10月22日 · High-dose aflibercept (8mg) for diabetic macular edema (DME) produces meaningful improvements in best-correct visual acuity (BCVA) across demographic subgroups such as sex, age, race, ethnicity, BCVA, and central retinal thickness, according to a subgroup analysis of the phase 2/3 PHOTON study (ClinicalTrials.gov Identifier: NCT04429503) presented at the American Academy of Ophthalmology 2024 ...
Stent Implant Efficacy Higher Without Cataract Surgery
June 25, 2024. Efficacy is higher for the Xen 45 gel stent implant as a standalone procedure than combined with cataract surgery. The Xen 45 gel stent implant provides effective, long-term treatment for open-angle glaucoma but there is a substantial rate of reoperation and needling, according to research published in British Journal of ...
Brolucizumab Outcomes Similar to Aflibercept in DME Treatment ...
2024年2月1日 · Brolucizumab 6 mg dosed every 4 weeks has demonstrated similar visual outcomes, but some superior anatomical outcomes to aflibercept 2 mg dosed at the same interval, according to results of the 52-week KINGFISHER Trial (ClinicalTrials.gov Identifier: NCT03917472) published in JAMA Ophthalmology. The study compared the safety and utility of the 2 drugs in trial participants with DME.
Preservative-Free Glaucoma Drop Option Well Tolerated
August 9, 2022. Latanoprost benzalkonium chloride (BAK)-free is efficacious and well tolerated during chronic use, according to recent findings published in Clinical Ophthalmology, providing a nonpreservative option for patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The phase 3, multicenter, open-label, nonrandomized ...